Scalp cooling treatment company Paxman will showcase the latest model of its Scalp Cooling System (PSCS) at Arab Health 2019.
The treatment prevents cancer patients from losing their hair with the aim of retaining a feeling of normality during chemotherapy.
The Cooling System, also known as the 'cold cap', alleviates the damage caused to the hair follicle by chemotherapy. It works by reducing the temperature of the scalp by a few degrees immediately before, during and after the administration of chemotherapy.
Made from lightweight silicone, the scalp cooling cap moulds to all head shapes and sizes. Liquid coolant passes through the cap, extracting heat from the person’s scalp, ensuring it remains at an even, constant temperature to minimise hair loss.
The new model employs an interactive user interface and touchscreen ensuring ease of use for clinical staff. Maintaining coolant levels is also simplified by a visual warning system and an easy-to-use self-drain coolant refill bag.
The new control pump manages the speed and coolant flow to improve the consistency of treatment. Manufacturing technique changes have also been introduced – the front cover of the scalp cooling machine is now injection moulded rather than RIM moulded – with the aim of improving the overall aesthetics of the system.
Richard Paxman, CEO at PAXMAN said: “Chemotherapy-induced hair loss is consistently ranked in the top five most distressing cancer chemotherapy side effects and we are working hard to ensure that cancer patients have a choice against hair loss. We are delighted to be able to offer scalp cooling to Middle Eastern patients and are keen to find new partners from across the region.”
